Short Interest Alert: Aethlon Medical Incorporated (NASDAQ:AEMD) Could Burn Your Long Portfolio After More Shorts

November 23, 2016 - By Peter Erickson   ·   0 Comments

Short Interest Alert: Aethlon Medical Incorporated (NASDAQ:AEMD) Could Burn Your Long Portfolio After More Shorts

The stock of Aethlon Medical Incorporated (NASDAQ:AEMD) registered an increase of 5.73% in short interest. AEMD’s total short interest was 138,300 shares in November as published by FINRA. Its up 5.73% from 130,800 shares, reported previously. With 13,300 shares average volume, it will take short sellers 10 days to cover their AEMD’s short positions. The short interest to Aethlon Medical Incorporated’s float is 2.06%. About 1,893 shares traded hands. Aethlon Medical, Inc. (NASDAQ:AEMD) has declined 16.06% since April 21, 2016 and is downtrending. It has underperformed by 21.39% the S&P500.

Aethlon Medical, Inc. is a medical device firm focused on creating devices for cancer, infectious disease and other life-threatening conditions. The company has a market cap of $36.12 million. The Firm operates through two divisions: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. It currently has negative earnings. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.

AEMD Company Profile

Aethlon Medical, Inc., incorporated on April 17, 1991, is a medical device firm focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Firm operates through two divisions: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome product candidates to diagnose and monitor neurological disorders and cancer.

More notable recent Aethlon Medical, Inc. (NASDAQ:AEMD) news were published by: Prnewswire.com which released: “Aethlon Medical Announces Corporate Update Presentation At Next Week’s 2016 …” on June 01, 2016, also Prnewswire.com with their article: “Aethlon Medical Announces Dengue Virus Study Approval, Chikungunya Virus …” published on February 03, 2016, Seekingalpha.com published: “Aethlon Medical Inc.: Total Scam Or Legit Company? (AEMD)” on December 08, 2014. More interesting news about Aethlon Medical, Inc. (NASDAQ:AEMD) were released by: Prnewswire.com and their article: “FinancialBuzz.com Exclusive NASDAQ MarketSite Interview with Aethlon Medical …” published on April 05, 2016 as well as Streetinsider.com‘s news article titled: “Aethlon Medical, Inc. (AEMD) Receives FDA Clinical Protocol Approval of Ebola …” with publication date: January 02, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>